1/22
Looks like no tags are added yet.
Adamantanes MOA
Block the M2 ion channel to inhibit viral uncoating
Adamantanes indications
Influenza A
Adamantanes adverse effects
CNS effects
Neuraminidase inhibitors
oseltamivir
Neuraminidase inhibitors MOA
inhibits neuraminidase enzyme which affects the release of viral particle, thereby reducing the amount of virus in the body
Neuraminidase indications
influenza A and B
RSV Monoclonal antibody
palivizumab
nirsevimab
clesrovimab
RSV monoclonal Antibody indications
less than 24 months old, high risk for severe disease
Remdesivir indications
COVID-19
Remdesivir MOA
adenosine nucleotide prodrug, inhibits RNA polymerase
Baricitinib indications
COVID-19 hospitalized patients requiring mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Baricitinib MOA
Inhibitor of Janus Kinase (JAK)
Baricitinib adverse effects
MI, sudden death, GI perforation, thrombosis
Monoclonal Antibodies MOA
bind to receptor binding domain of SARS-CoV-2 spike protein, not useful for Omnicron, many not authorized for use
Monoclonal Antibodies drugs still used
Tocilizumab and Sarilumab, IL-6 receptor inhibitors
Vilobelimab indicated use
COVID-19 hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation or ECMO
Ritonavir-boosted nirmatrelvir indications
1st line treatment for mild to moderate COVID in people 12+ at high risk for severe illness
Ritonavir-boosted nirmatrelvir MOA
inhibitor of SARS-CoV-2 main protease
Ritonavir-boosted nirmatrelvir adverse effects
GI, altered taste, hepatitis, increase transaminase
Ensitrelvir MOA
SARS-CoV-2 main protease
Ensitrelvir indications
post exposure prophylaxis in people ages 12+ following contact with an individual who has COVID-19
Ensitrelvir contraindications
Pregnancy, below 12 y/o
Indications for COVID-19 vaccines
65+, or 6 months + for high risk people